Drug Index


Mechanism :

Denosumab is a monoclonal antibody with affinity for nuclear factor-kappa ligand (RANKL).

Indication :

  • Hypercalcemia of malignancy
  • Glucocorticoid- induced osteoporosis
  • Bone metastases from solid tumors
  • Giant cell tumor of bone
  • Osteoporosis/bone loss
  • Multiple myeloma

Contraindications :

Hypersensitivity (systemic) to denosumab or any component of the formulation; pre-existing hypocalcemia; pregnancy.

Dosing :

13 to 17 years:
Giant cell tumor of bone:
SC: 120 mg once every 4 weeks; during the first month, give an additional 120 mg on days 8 and 15.

Adverse Effect :

Peripheral edema, hypertension, fatigue, headache, skin rash, dermatitis, eczema, hypophosphatemia, hypocalcemia, diarrhea, nausea, constipation, anemia, thrombocytopenia, weakness, dyspnea, cough.

Interaction :

Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Immunosuppressants: Denosumab may enhance the adverse/toxic effect of immunosuppressants. Specifically, the risk for serious infections may be increased.

Hepatic Dose :

No dosage adjustments are recommended.
02/21/2024 21:59:33 Denosumab
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0